Reimagining cholinergic therapy for Alzheimer’s disease

Cites (322)

Items 201–323 of 323

1. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats
   Carla Scali, Fiorella Casamenti, Arianna Bellucci, Camilla Costagli, Bernard H Schmidt, Giancarlo Pepeu · 2002 · Journal of Neural Transmission
2. Stimulation in Supplementary Motor Area Versus Motor Cortex for Freezing of Gait in Parkinson's Disease
   Sang Jin Kim, Sung Hwa Paeng, Suk Yun Kang · 2018 · Journal of Clinical Neurology
3. Long-term progression of Alzheimer's disease in patients under antidementia drugs
   Gillette‐Guyonnet, Sophie, Andrieu, Sandrine, Nourhashemi, Fati, Gardette, Virginie, Coley, Nicola, Cantet, Christelle, Gauthier, Serge, Ousset, Pierre‐Jean, Vellas, Bruno, REAL.FR study group · 2011 · Alzheimer's & Dementia
4. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease
   Azadeh Karami, Helga Eyjolfsdottir, Swetha Vijayaraghavan, Göran Lind, Per M. Almqvist, Ahmadul Kadir, Bengt Linderoth, Niels Andreasen, Kaj Blennow, Anders E. Wall et al. · 2015 · Alzheimer s & Dementia
5. Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats
   R.H Wang, Corina Bejar, Marta Weinstock · 2000 · Neuropharmacology
6. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
   Roger Alan Bullock, Howard Bergman, Jacques Touchon, Giuseppe Gambina, Yunsheng He, Jennifer Nagel, Roger M. Lane · 2006 · Current Medical Research and Opinion
7. Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease
   Matthew J. Barrett, Jamie C. Blair, Scott A. Sperling, Mark E. Smolkin, T. Jason Druzgal · 2018 · Neurology
8. AF710B, an M1/sigma‐1 receptor agonist with long‐lasting disease‐modifying properties in a transgenic rat model of Alzheimer's disease
   Hélène Hall, M. Florencia Iulita, Palma Gubert, Lisi Flores Aguilar, Adriana Ducatenzeiler, Abraham Fisher, A. Claudio Cuello · 2017 · Alzheimer s & Dementia
9. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
   Marwan Noel Sabbagh, Jeffrey L. Cummings · 2011 · BMC Neurology
10. Design and Synthesis of γ- and δ-Lactam M 1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M 1 -Selective PAM with Weak Agonist Activity
    Jennifer E. Davoren, Michelle R. Garnsey, Betty A. Pettersen, Michael A. Brodney, Jeremy R. Edgerton, Jean-Philippe Fortin, Sarah Grimwood, Anthony R. Harris, Stephen G. Jenkinson, Terry Kenakin et al. · 2017 · Journal of Medicinal Chemistry
11. Acetylcholinesterase Activity and Neurodevelopment in Boys and Girls
    Jose Ricardo Suarez-Lopez, John H. Himes, David R. Jacobs, Bruce H. Alexander, Megan R. Gunnar · 2013 · PEDIATRICS
12. Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease
    Scacchi, Renato, Gambina, Giuseppe, Broggio, Elisabetta, Corbo, Rosa Maria · 2014 · International Journal of Geriatric Psychiatry
13. Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis
    Hideo Tsukada, Shingo Nishiyama, Dai Fukumoto, Hiroyuki Ohba, Kengo Sato, Takeharu Kakiuchi · 2004 · Synapse
14. Adverse Drug Reactions Reported With Cholinesterase Inhibitors
    Edeltraut Kröger, Marie Mouls, Machelle Wilchesky, Mieke Berkers, Pierre‐Hugues Carmichael, Rob J. van Marum, Patrick Cyriel Souverein, Toine C. G. Egberts, Marie‐Laure Laroche · 2015 · Annals of Pharmacotherapy
15. Delivery of NGF to the Brain: Intranasal versus Ocular Administration in Anti-NGF Transgenic Mice
    Simona Capsoni, Sonia Covaceuszach, Gabriele Ugolini, Francesca Spirito, Domenico Vignone, Barbara Stefanini, Gianluca Amato, Antonino Cattaneo · 2009 · Journal of Alzheimer s Disease
16. Cholinergic Surveillance over Hippocampal RNA Metabolism and Alzheimer's-Like Pathology
    Benjamin Kolisnyk, Mohammed Al‐Onaizi, Lilach Soreq, Shahar Barbash, Uriya Bekenstein, Nejc Haberman, Geula Hanin, Maxine T. Kish, Jussemara Souza da Silva, Margaret L. Fahnestock et al. · 2016 · Cerebral Cortex
17. Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease
    Tiffini Voss, Jerry Li, Jeffrey L. Cummings, Martin Rhys Farlow, Christopher A. Assaid, Samar Froman, Heather Leibensperger, Linda Snow‐Adami, Kerry Budd McMahon, Michael F. Egan et al. · 2018 · Alzheimer s & Dementia Translational Research & Clinical Interventions
18. Donepezil Impairs Memory in Healthy Older Subjects: Behavioural, EEG and Simultaneous EEG/fMRI Biomarkers
    Joshua Henk Balsters, Redmond G O’Connell, Mary P. Martin, Alessandra Galli, Sarah M. Cassidy, Sophia M. Kilcullen, Sonja Delmonte, Sabina Brennan, Jim F. Meaney, Andrew J Fagan et al. · 2011 · PLoS ONE
19. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment
    Steven H. Ferris, Agneta K. Nordberg, Hilkka S. Soininen, Taher Darreh‐Shori, Roger M. Lane · 2009 · Pharmacogenetics and Genomics
20. M1 muscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MAPK/ERK-independent pathways
    Corinne Leloup, Daniel M. Michaelson, Abraham Fisher, Tobias Hartmann, Konrad T. Beyreuther, Reuven Stein · 2000 · Cell Death and Differentiation
21. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study
    Kosuke Matsuzono, Nozomi Hishikawa, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Yumiko Nakano, Koji Abe · 2015 · Journal of Alzheimer s Disease
22. Activation of Muscarinic Receptors Inhibits औ-Amyloid Peptide-induced Signaling in Cortical Slices
    Zhenglin Gu, Ping Zhong, Zhen Yan · 2003 · Journal of Biological Chemistry
23. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
    Miriam Scarpa, Sarah Hesse, Sophie J. Bradley · 2020 · Advances in pharmacology
24. Cholinergic activity correlates with reserve proxies in Alzheimer's disease
    Valentina Garibotto, Marco Tettamanti, Alessandra Marcone, Ioana Florea, Andrea Panzacchi, Rosamaria Moresco, Jere R. Virta, Juha O. Rinne, Stefano Francesco Cappa, Daniela Perani · 2013 · Neurobiology of Aging
25. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment
    Wattmo, Carina, Wallin, Åsa K., Londos, Elisabet, Minthon, Lennart · 2011 · Alzheimer Disease & Associated Disorders
26. A prion protein connection
    Moustapha Cissé, Lennart Mucke · 2009 · Nature
27. Volume Loss of the Nucleus Basalis of Meynert is Associated with Atrophy of Innervated Regions in Mild Cognitive Impairment
    José Luis Cantero, László Záborszky, Mercedes Atienza · 2016 · Cerebral Cortex
28. [11C]-MP4A PET Cholinergic Measurements in Amnestic Mild Cognitive Impairment, Probable Alzheimer's Disease, and Dementia with Lewy Bodies: A Bayesian Method and Voxel-Based Analysis
    Marcone, Alessandra, Garibotto, Valentina, Moresco, Rosa Maria, Florea, Ioana, Panzacchi, Andrea, Carpinelli, Assunta, Virta, Jere R., Tettamanti, Marco, Borroni, Barbara, Padovani, Alessandro et al. · 2012 · Journal of Alzheimer's Disease
29. Do Cholinesterase Inhibitors Act Primarily on Attention Deficit? A Naturalistic Study in Alzheimer's Disease Patients
    Laura Bracco, Valentina Bessi, Sonia Padiglioni, Sandro Marini, Giancarlo Pepeu · 2014 · Journal of Alzheimer s Disease
30. Evolutional Aspects of Alzheimer's Disease Pathogenesis
    Heiko Braak, Kelly Del Tredici · 2012 · Journal of Alzheimer s Disease
31. Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer’s Disease
    Enrica Cavedo, for the Hippocampus Study Group, Bruno Dubois, Olivier Colliot, Simone Lista, Bernard Croisile, Guy Louis-Tisserand, Jacques Touchon, Alain Bonafé, Pierre‐Jean Ousset et al. · 2016 · The Journal of Clinical Psychiatry
32. Muscarinic M1 Receptor Overstimulation Disrupts Working Memory Activity for Rules in Primate Prefrontal Cortex
    Vijayraghavan, Susheel, Major, Alex James, Everling, Stefan · 2018 · Neuron
33. Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders
    Daniel Erskine, John‐Paul Taylor, Geor Bakker, Alastair Brown, Tim C. G. Tasker, Pradeep J. Nathan · 2019 · Drug Discovery Today
34. Efficacy and safety of pharmacotherapy for Alzheimer’s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials
    M. Seibert, Viktoria Mühlbauer, Jill A. Holbrook, Sebastian Voigt-Radloff, Simone Brefka, Dhayana Dallmeier, Michael Dieter Denkinger, Carlos Schönfeldt‐Lecuona, Stefan Klöppel, Christine A. F. Von Arnim · 2021 · Alzheimer s Research & Therapy
35. Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
    Wallin, Åsa, Minthon, Wattmo, Carina · 2011 · Neuropsychiatric Disease and Treatment
36. Sex influences on cholinesterase inhibitor treatment in elderly individuals with alzheimer's disease
    Wendy M. Haywood, Elizabeta B. Mukaetova‐Ladinska · 2006 · The American Journal of Geriatric Pharmacotherapy
37. Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery
    Harald Juergen Hampel, Andrea Vergallo, Filippo Caraci, A. Claudio Cuello, Pablo Lemercier, Bruno J. Vellas, Kelly Virecoulon Giudici, Filippo Baldacci, Britta Hänisch, Marion Haberkamp et al. · 2020 · Neuropharmacology
38. Site‐Specific Dephosphorylation of Tau of Apolipoprotein E‐Deficient and Control Mice by M1 Muscarinic Agonist Treatment
    Idit Genis, Abraham Fisher, Daniel M. Michaelson · 1999 · Journal of Neurochemistry
39. Anticholinergic Burden and Risk of Stroke and Death in People with Different Types of Dementia
    Edwin C.K. Tan, Maria Eriksdotter, Sara Garcia Ptacek, Johan Fastbom, Kristina Johnell · 2018 · Journal of Alzheimer s Disease
40. Effect of cholinesterase inhibitors on attention
    Giancarlo Pepeu, Maria Grazia Giovannini, Laura Bracco · 2012 · Chemico-Biological Interactions
41. Word comprehension in temporal cortex and Wernicke area
    Marsel M. Mesulam, Benjamin M. Rader, Jaiashre Sridhar, Matthew J. Nelson, JungMoon Hyun, ALFRED W. RADEMAKER, Changiz Geula, Eileen H. Bigio, Cynthia K. Thompson, Tamar D. Gefen et al. · 2018 · Neurology
42. The Brain Cholinergic System
    Ezio Giacobini, Giancarlo Pepeu · 2006 · CRC Press eBooks
43. Chronic Administration of Scopolamine Increased GSK3βP9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats
    Maricarmen Hernández Rodríguez, Ivonne Maciel Arciniega-Martínez, Iohanan Daniel García-Marín, José Correa‐Basurto, Martha Cecilia Rosales‐Hernández · 2020 · Molecular Neurobiology
44. Sortilins in Neurotrophic Factor Signaling
    Simon Glerup, Anders Nykjær, Christian Bjerggaard Vægter · 2014 · Handbook of experimental pharmacology
45. Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors
    Stefan Johannes Teipel, Enrica Cavedo, Harald Juergen Hampel, Michel J. Grothe, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer Precision Medicine Initiative (APMI) · 2018 · Frontiers in Neurology
46. Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients
    Zhenguang Li, Zhancai Yu, Jinbiao Zhang, Jing Wang, Chao Sun, Pengfei Wang, Jiangshan Zhang · 2015 · European Neurology
47. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy
    Wallin, Å.K., Gustafson, L., Sjögren, M., Wattmo, C., Minthon, L. · 2004 · Dementia and Geriatric Cognitive Disorders
48. Differential expression of p140trk, p75NGFR and growth-associated phosphoprotein-43 genes in nucleus basalis magnocellularis, thalamus and adjacent cortex following neocortical infarction and nerve growth factor treatment
    Bonald Cavalcante de Figueiredo, Małgorzata Skup, Annie M. Bedard, Wolfram Tetzlaff, A. Claudio Cuello · 1995 · Neuroscience
49. Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice
    Rohan Van Der Putt, Catherine Dineen, David Janes, Hugh G. Series, Rupert H. McShane · 2006 · International Journal of Geriatric Psychiatry
50. A population-based study of dosing and persistence with anti-dementia medications
    Linda Brewer, Kathleen Bennett, Cora McGreevy, David James Williams · 2013 · European Journal of Clinical Pharmacology
51. Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer’s Disease Mouse Model
    Evan P. Lebois, Jason P. Schroeder, Thomas J. Esparza, Thomas M. Bridges, Craig W. Lindsley, Peter Jeffrey Conn, David L. Brody, John Scott Daniels, Allan I. Levey · 2017 · ACS Chemical Neuroscience
52. Impaired cholinergic transmission in patients with Parkinson's disease and olfactory dysfunction
    Viviana Versace, Patrick Benjamin Langthaler, Luca Sebastianelli, Yvonne Höller, Francesco Brigo, Andrea Orioli, Leopold LS. Saltuari, Raffaele Nardone · 2017 · Journal of the Neurological Sciences
53. ERK1-independent α-secretase cut of β-amyloid precursor protein via M1 muscarinic receptors and PKCα/ε
    Moustapha Cissé, Ursula Braun, Michael Leitges, Abraham Fisher, Gilles Pagès, Frédéric Checler, Bruno Vincent · 2011 · Molecular and Cellular Neuroscience
54. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory
    Bentley, P., Driver, J., Dolan, R.J. · 2009 · Brain
55. Cardiovascular Effects and Risk of Syncope Related to Donepezil in Patients with Alzheimer???s Disease
    Philippe Bordier, Stéphane Garrigue, Stephane Lanusse, Julien Margaine, Frederic Robert, Laurent Gencel, Alexia Lafitte · 2006 · CNS Drugs
56. M1 muscarinic acetylcholine receptor dysfunction in moderate Alzheimer’s disease pathology
    Jee Hyun Yi, Daniel J. Whitcomb, Se Jin Park, Celia Martinez-Perez, Saviana Antonella Barbati, Scott J. Mitchell, Kwangwook Cho · 2020 · Brain Communications
57. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
    Rowan Pentz, M. Florencia Iulita, Adriana Ducatenzeiler, Laura Videla, Bessy Benejam, María Carmona‐Iragui, Rafael Blesa, Alberto Lleó, Juan Fortea, A. Claudio Cuello · 2020 · Alzheimer s & Dementia
58. Chapter 32: Trophic responses of forebrain cholinergic neurons: a discussion
    A. Claudio Cuello · 1993 · Progress in brain research
59. C. elegans neurons have functional dendritic spines
    Andrea Cuentas-Condori, Ben Mulcahy, Siwei He, Sierra D. Palumbos, Mei Zhen, David M. Miller · 2019 · eLife
60. Nerve growth factor selectively regulates expression of transcripts encoding ribosomal proteins
    James M. Angelastro, Beáta Törőcsik, Lloyd A. Greene · 2002 · BMC Neuroscience
61. Can CSF biomarkers or pre‐treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
    A. Wallin, Oskar Hansson, Kaj Blennow, Elisabet Londos, Lennart Minthon · 2009 · International Journal of Geriatric Psychiatry
62. Preclinical to Human Translational Pharmacology of the Novel M1 Positive Allosteric Modulator MK-7622
    Jason M. Uslaner, Scott D. Kuduk, Marion Wittmann, Henry S. Lange, Steve V. Fox, Chris Min, Natasa Pajkovic, Dawn Harris, Caroline Cilissen, Chantal Mahon et al. · 2018 · Journal of Pharmacology and Experimental Therapeutics
63. Anterograde vs. retrograde degeneration of the nucleus basalis medialis in Alzheimer's disease.
    R C Pearson, T.P.S. Powell · 1987 · PubMed
64. The rationale for deep brain stimulation in Alzheimer’s disease
    Zaman Mirzadeh, Ausaf Bari, Andrés M. Lozano · 2015 · Journal of Neural Transmission
65. Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease
    Cassia Overk, Christian C. Felder, Yuan Tu, Douglas A. Schober, Kelly R. Bales, Joanne Wuu, Elliott Jay Mufson · 2010 · Journal of Chemical Neuroanatomy
66. Muscarinic cholinoceptive neurons in the frontal cortex in Alzheimer's disease
    Hannsjörg Schröder, Ezio Giacobini, Robert G. Struble, Paul G.M. Luiten, Eddy A. van der Zee, Karl Zilles, Arthur Donny Strosberg · 1991 · Brain Research Bulletin
67. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer’s disease
    Katy A. Chalmers, Gordon Keith Wilcock, Harry V. Vinters, Elaine King Perry, Robert Perry, Clive G. Ballard, Seth Love · 2009 · Journal of Neurology
68. Quantitative Determination of Acetylcholinesterase Activity in Individual Nerve Cells
    Ezio Giacobini, JOSEPH ZAJIČEK · 1956 · Nature
69. Trophic Factors in Neurologic Disease
    S S Stewart, Stanley H. Appel · 1988 · Annual Review of Medicine
70. Rita Levi-Montalcini and the discovery of NGF, the first nerve cell growth factor.
    Luigi Aloe · 2011 · PubMed
71. Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons; implications for Alzheimer's disease.
    Franz F. Hefti, Bruno E. Will · 1987 · PubMed
72. Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons
    Simon T. M. Allard, Marie L. Jacobs, Sonia Do Carmo, A. Claudio Cuello · 2018 · Neurobiology of Aging
73. Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services
    Carina Wattmo, Elisabet Londos, Lennart Minthon · 2015 · Dementia and Geriatric Cognitive Disorders
74. Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementia
    Yi‐Ting Lin, Ping‐Hsun Wu, Cheng‐Sheng Chen, Yi‐Hsin Yang, Yuan‐Han Yang · 2016 · Scientific Reports
75. A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe /PSEN1ΔE9 mice
    Khaled S. Abd‐Elrahman, Shaarika Sarasija, Tash‐Lynn L. Colson, Stephen S. G. Ferguson · 2021 · British Journal of Pharmacology
76. Chapter 30 New trends in cholinergic therapy for Alzheimer disease: nicotinic agonists or cholinesterase inhibitors?
    Ezio Giacobini · 1996 · Progress in brain research
77. Nonmedical Influences on the Use of Cholinesterase Inhibitors in Dementia Care
    Carol E. Franz, Judith C. Barker, Richard L. Kravitz, Yvette G. Flores, Sheila Krishnan, Ladson Hinton · 2007 · Alzheimer Disease & Associated Disorders
78. Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease
    Carina Wattmo, Elisabet Londos, Lennart Minthon · 2014 · BMC Neurology
79. Extrasynaptic Muscarinic Acetylcholine Receptors on Neuronal Cell Bodies Regulate Presynaptic Function in Caenorhabditis elegans
    Jason Chan, Trisha A. Staab, Han Wang, Chiara Mazzasette, Z. Butte, Derek Sieburth · 2013 · Journal of Neuroscience
80. Sex dimorphisms in the cognitive-enhancing action of the Alzheimer’s drug donepezil in aged Rhesus monkeys
    Jerry J. Buccafusco, William James Jackson, J. D. Stone, Alvin V. Terry · 2003 · Neuropharmacology
81. Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: Effects of sex hormone withdrawal
    Gracielle Alves-Amaral, Marcelo Pires-Oliveira, Ana Luiza Andrade-Lopes, Tiago Chiavegatti, Rosely Oliveira Godinho · 2010 · Chemico-Biological Interactions
82. A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome
    M. Florencia Iulita, Filippo Caraci, A. Claudio Cuello · 2016 · CNS & Neurological Disorders - Drug Targets
83. Metrifonate: Overview of Safety and Efficacy
    Jeffrey L. Cummings · 1998 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
84. Long-Term Non-Invasive Treatment via Intranasal Administration of Nerve Growth Factor Protects the Human Brain in Frontotemporal Dementia associated with Corticobasal Syndrome: A Pilot Study
    Alberto de Bellis, Massimo de Bellis, Luigi Aloe · 2018 · Journal of Alzheimer s Disease Reports
85. Isoform-specific contribution of protein kinase C to prion processing
    Moustapha Cissé, Krystel Louis, Uschi Braun, Bernard P. Mari, Michael Leitges, Barbara E. Slack, Abraham Fisher, Patrick Auberger, Frédéric Checler, Bruno Vincent · 2008 · Molecular and Cellular Neuroscience
86. Basal forebrain metabolism in Alzheimer's disease continuum: relationship with education
    Brandt Nicolas, Alessandra Dodich, Daniela Perani, Ratib Osman, Sara Trombella, Giovanni Battista Frisoni, Valentina Garibotto · 2019 · Neurobiology of Aging
87. Deep Brain Stimulation in Alzheimer’s Disease: Targeting the Nucleus Basalis of Meynert
    Yusi Chen, Kai Shu, Huicong Kang · 2021 · Journal of Alzheimer s Disease
88. Long-term rivastigmine treatment in a routine clinical setting
    Lennart Minthon, A. Wallin, Sam Eriksson, Carina Wattmo, Nancy C. Andreasen · 2008 · Acta Neurologica Scandinavica
89. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
    Steven H. Ferris, Frederick A. Schmitt, Judith A. Saxton, Sharon Richardson, Joan A. Mackell, Yijun Sun, Yikang Xu · 2011 · Alzheimer s Research & Therapy
90. Potential Role of Neuroimaging Markers for Early Diagnosis of Dementia in Primary Care
    Stefan Johannes Teipel, Ingo Kilimann, Jochen René Thyrian, Stefan Klöppel, Wolfgang U. Hoffmann · 2017 · Current Alzheimer Research
91. Immunotoxin Lesion of the Cholinergic Nucleus Basalis Causes Aβ Deposition: Towards a Physiologic Animal Model of Alzheimers Disease
    Thomas G. Beach, D. Walker, Sue Li, S. Scott, Kerry A. Layne, A. Newell, Pamela E. Potter, Robert A. Durham, Mark R. Emmerling, Scott D. Webster · 2003 · Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents
92. Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson’s disease
    James Gratwicke, Thomas Foltynie · 2017 · Brain
93. Tardive neurotoxicity of anticholinergic drugs: A review
    Sina Marzoughi, Ankur Banerjee, Catherine Ruth Jutzeler, Marco A. M. Prado, Jan Rösner, Jacquelyn J. Cragg, Neil R. Cashman · 2020 · Journal of Neurochemistry
94. Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo : A Microdialysis Study
    Tobias Welt, Luka Kulic, Sarah E. Hoey, Jordan McAfoose, Claudia B. Späni, Antonella Santuccione Chadha, Abraham Fisher, Roger M. Nitsch · 2015 · Journal of Alzheimer s Disease
95. Cortical afferent inhibition abnormalities reveal cholinergic dysfunction in Parkinson’s disease: a reappraisal
    Raffaele Nardone, Francesco Brigo, Viviana Versace, Yvonne Höller, Frediano Tezzon, Leopold LS. Saltuari, Eugen Trinka, Luca Sebastianelli · 2017 · Journal of Neural Transmission
96. Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease
    M. Wienrich, Angelo Ceci, Helmut A. Ensinger, Wolfram Gaida, Klaus D. Mendla, Takeshi Osugi, Andreas Raschig, Thomas W. Weiser · 2002 · Drug Development Research
97. Neuronotrophic Factors in Cellular Functional and Cognitive Repair of Adult Brain
    Silvio S. Varon, Theo Hagg, Barry Fass, L. Vahlsing, Marston Manthorpe · 1989 · Pharmacopsychiatry
98. Tacrine in Alzheimer's disease
    Sarah A. Eagger, Raymond Levy, Barbara Jacquelyn Sahakian · 1992 · Acta Neurologica Scandinavica
99. MCI treatment trials: failure or not?
    Ronald Carl Petersen · 2007 · The Lancet Neurology
100. Cholinesterase inhibitors and the risk of pulmonary disorders in hospitalized dementia patients.
     Raphael Helou, Mounir Rhalimi · 2010 · PubMed
101. National patterns of dementia treatment among elderly ambulatory patients.
     Mary K. Maneno, Euni Lee, Anthony K. Wutoh, Ilene H. Zuckerman, Patrice Jackson, Fredric A. Lombardo, Kenneth R. Scott, Zhenyi Xue · 2006 · PubMed Central
102. Metrifonate: A Cholinesterase Inhibitor for Alzheimer's Disease Therapy
     Lon S. S. Schneider, Ezio Giacobini · 1999 · CNS Drug Reviews
103. Delusions and visual hallucinations in a patient with Parkinson's disease with dementia showing pronounced Lewy body pathology in the nucleus basalis of Meynert
     Kenji Sakai, Tokuhei Ikeda, Chiho Ishida, Kiyonobu Komai, Masahito Yamada · 2019 · Neuropathology
104. Cholinergic Deep Brain Stimulation for Memory and Cognitive Disorders
     Saravanan Subramaniam, David T. Blake, Christos Constantinidis · 2021 · Journal of Alzheimer s Disease
105. Long-term trihexyphenidyl exposure alters neuroimmune response and inflammation in aging rat: relevance to age and Alzheimer’s disease
     Yuqi Huang, Zhe Zhao, Xiaoli Wei, Yong Mu Zheng, Jianqiang Yu, Jian‐Quan Zheng, Liyun Wang · 2016 · Journal of Neuroinflammation
106. Potential for intermittent stimulation of nucleus basalis of Meynert to impact treatment of alzheimer's disease
     David T. Blake, Alvin V. Terry, Marc R. Plagenhoef, Christos Constantinidis, Ruifeng Liu · 2017 · Communicative & Integrative Biology
107. Selective Benefit of Donepezil on Oral Naming in Alzheimer's Disease in Men Compared to Women
     Meghan L. Davis, Anna M. Barrett · 2009 · CNS Spectrums
108. Pharmacokinetics and Tissue Distribution of Galantamine and Galantamine-related Radioactivity after Single Intravenous and Oral Administration in the Rat
     Ludy van Beijsterveldt, R Geerts, Tom Verhaeghe, Bart Willems, Wilhelmina Bode, Karel Lavrijsen, Meuldermans Willem · 2011 · Arzneimittelforschung
109. A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia
     Jaime McDonald, Emmanuelle Pourcher, Alexandra Nadeau, Philippe Corbeil · 2018 · Clinical Neuropharmacology
110. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer’s Disease
     Pasi Lampela, Anna‐Maija Tolppanen, Marjaana Koponen, Antti J. Tanskanen, Jari Tiihonen, Sirpa A. Hartikainen, Heidi T. Taipale · 2020 · Journal of Alzheimer s Disease
111. Aged rhesus monkeys: Cognitive performance categorizations and preclinical drug testing
     Marc R. Plagenhoef, Patrick M. Callahan, Wayne D. Beck, David T. Blake, Alvin V. Terry · 2021 · Neuropharmacology
112. Use of Anti-Dementia Drugs Reduces the Risk of Potentially Inappropriate Medications: A Secondary Analysis of a Nationwide Survey of Prescribing Pharmacies
     Yusuke Suzuki, Mikio Sakakibara, Nariaki Shiraishi, Hitoshi Komiya, Masahiro Akishita, Masafumi Kuzuya · 2020 · Dementia and Geriatric Cognitive Disorders
113. Gender Differences in the Pharmacokinetics of Rivastigmine in Rats
     Karthik Arumugam, Mallikarjuna Chamallamudi, Surulivelrajan Mallayasamy, Subramanian Ganesan, Gopal Venkatesh Shavi, Averineni Ranjithkumar, Ravindranath Reddy DR, Krishnamurthy Bhat, N Udupa · 2011 · Arzneimittelforschung
114. Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model
     Ziyan Li, Kaili Jia, Yale Duan, Dong Wang, Zongli Zhou, Suzhen Dong · 2017 · Molecular Medicine Reports
115. The Pharmacology of Neurotrophic Factors
     A. Claudio Cuello, H. Thoenen · 1995 · Birkhäuser Basel eBooks
116. Reduced substantia innominata volume mediates contributions of microvascular and macrovascular disease to cognitive deficits in Alzheimer's disease
     Gurpreet Jaswal, Walter Swardfager, Fuqiang Gao, Sean M. Nestor, Anoop Ganda, Hugo Cogo‐Moreira, Demetrios J. Sahlas, Donald T. Stuss, Alan R. Moody, Sandra E. Black · 2018 · Neurobiology of Aging
117. Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study
     Fumihiko Yasuno, Hiroyuki Minami · 2021 · International Journal of Geriatric Psychiatry
118. The effects of rivastigmine on behavioral symptoms in severe ad patients in a nursing home setting
     Ravi Anand, Barbara Koumaras, Richard D. Hartman · 2000 · Neurobiology of Aging
119. Cholinergic forebrain density loss in Parkinson disease
     Nicolaas I. Bohnen, Stefan Johannes Teipel · 2018 · Neurology
120. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study
     Sanika Rege, Ryan M. Carnahan, Michael L. Johnson, Hua Chen, Holly Michelle Holmes, Rajender R. Aparasu · 2021 · Drugs & Aging
121. Cerebrovascular Pathology and Responsiveness to Treatment in Alzheimer’s Disease: A Systematic Review
     Charlotte Bentham, Matteo De Marco, Annalena Venneri · 2021 · Current Alzheimer Research
122. Human memory and the cholinergic system. A relationship to aging
     Drachman, David A., Leavitt, Janet · 1974 · The Journal of the American Medical Association (JAMA) Network (American Medical Association)
123. Untitled work
     2000 · 10.1002/1531-8249(200012)48:6